JAAD:Ixekizumab 的长期疗效和安全性

2021-09-06 医路坦克 MedSci原创

Ixekizumab 是一种有效的中度至重度斑块状银屑病治疗方法，具有良好的安全性特征。ixekizumab 疗法适用于斑块状银屑病患者的长期治疗。

Ixekizumab 是一种有效的中度至重度斑块状银屑病治疗方法，具有良好的安全性特征。患者在264 周期间经历了持续的皮肤清除反应率和一致的安全性。总体而言，Ixekizumab 疗法适用于斑块状银屑病患者的长期治疗.

患者 (N=1346) 以 1:2:2:2 的比例随机接受皮下注射安慰剂、依那西普 50 毫克每周两次、IXE 毫克每 2 周 (Q2W) 或每 4 周 (Q4W) 在初始剂量 IXE 160 后毫克。在第 12 周，患者使用 IXEQ4W 给药进入长期延长 (LTE) 期，并可能在第 60 周后升级至 Q2W。报告了意向治疗人群的 IXEQ2W/Q4W 组的疗效。接受至少 1 剂 IXEQ2W/Q4W 的患者报告了安全性。

患者在第 264 周期间经历了持续的皮肤清除反应率和一致的安全性。总体而言，ixekizumab 疗法适用于斑块状银屑病患者的长期治疗。

文献来源：Blauvelt A, Lebwohl MG, Mabuchi T，Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.J Am Acad Dermatol 2021 Aug;85(2)

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Dec 19 13:03:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912673, encodeId=8f4d19126e3c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 18 04:03:54 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10163, encryptionId=ed671016333, topicName=ixekizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4f8326724, createdName=snowpeakxu, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033124, encodeId=56d8103312458, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Sep 06 14:03:54 CST 2021, time=2021-09-06, status=1, ipAttribution=)]
2021-12-19 经常头晕

#疗效和安全性#

27 0
[GetPortalCommentsPageByObjectIdResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Dec 19 13:03:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912673, encodeId=8f4d19126e3c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 18 04:03:54 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10163, encryptionId=ed671016333, topicName=ixekizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4f8326724, createdName=snowpeakxu, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033124, encodeId=56d8103312458, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Sep 06 14:03:54 CST 2021, time=2021-09-06, status=1, ipAttribution=)]
2022-07-18 snf701207

#mAb#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Dec 19 13:03:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912673, encodeId=8f4d19126e3c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 18 04:03:54 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10163, encryptionId=ed671016333, topicName=ixekizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4f8326724, createdName=snowpeakxu, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033124, encodeId=56d8103312458, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Sep 06 14:03:54 CST 2021, time=2021-09-06, status=1, ipAttribution=)]
2021-09-08 snowpeakxu

#ixekizumab#

35 0
[GetPortalCommentsPageByObjectIdResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Dec 19 13:03:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912673, encodeId=8f4d19126e3c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 18 04:03:54 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10163, encryptionId=ed671016333, topicName=ixekizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4f8326724, createdName=snowpeakxu, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033124, encodeId=56d8103312458, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Sep 06 14:03:54 CST 2021, time=2021-09-06, status=1, ipAttribution=)]
2021-09-08 gjsgj

#长期疗效#

47 0
[GetPortalCommentsPageByObjectIdResponse(id=1721070, encodeId=c5f01e210704f, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sun Dec 19 13:03:54 CST 2021, time=2021-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912673, encodeId=8f4d19126e3c6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 18 04:03:54 CST 2022, time=2022-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10163, encryptionId=ed671016333, topicName=ixekizumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4f8326724, createdName=snowpeakxu, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553522, encodeId=a5d0155352260, content=<a href='/topic/show?id=3b409e02804' target=_blank style='color:#2F92EE;'>#长期疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97028, encryptionId=3b409e02804, topicName=长期疗效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2a14383573, createdName=gjsgj, createdTime=Wed Sep 08 02:03:54 CST 2021, time=2021-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033124, encodeId=56d8103312458, content=谢谢梅斯提供这么好的信息，学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Mon Sep 06 14:03:54 CST 2021, time=2021-09-06, status=1, ipAttribution=)]
2021-09-06 内科新手

谢谢梅斯提供这么好的信息，学到很多

61 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

皮肤与性病

JAAD:Ixekizumab 的长期疗效和安全性

相关资讯

科室

工具

服务